Fortitude Family Office’s Adaptive Biotechnologies ADPT Stock Holding History

Fortitude Family Office’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.97K	Buy	+92	New	+$1.41K	﹤0.01%	1486

Other funds holding ADPT

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Fortitude Family Office's ADPT Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 92 shares worth $1.97K. The stake represents ﹤0.01% of the portfolio and ranks #1486 among its holdings.

49 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Fortitude Family Office held 92 shares of Adaptive Biotechnologies worth $1.97K as of Q2 2026.
Adaptive Biotechnologies was a new Fortitude Family Office position in Q2 2026.
Adaptive Biotechnologies made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1486 holding.
49 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.